Tilray Brands, Inc. (TLRY, Financial) experienced a significant stock movement with a 5% decline in its share price. The stock is currently trading at $0.950 per share with a trading volume of 54.9975 million shares, a turnover rate of 5.89%, and a price fluctuation of 5.99%.
Recent financial reports show that Tilray achieved a revenue of $211 million but recorded a net loss of $85.34 million, translating to earnings per share of -$0.10. The company has a gross profit of $38.29 million and a negative price-to-earnings ratio of -3.17. Among 15 rating institutions, 27% recommend buying the stock, while 73% suggest holding it, with no sell recommendations.
Within the pharmaceutical industry, where Tilray operates, there was an overall decline of 0.76%. However, some related stocks such as Quantum Biopharma Ltd., Kamada Ltd., and Avadel Pharmaceuticals Plc showed significant gains. Quantum Biopharma Ltd. and Aurora Cannabis were notably active, with turnover rates of 76.36% and 10.07%, respectively. Stocks with large price fluctuations included Quantum Biopharma Ltd. and Cyclo Therapeutics Inc., with amplitudes of 33.69% and 28.46%, respectively.
Tilray, a Canadian company, specializes in the cultivation and sale of medical and recreational cannabis. In 2021, it underwent a reverse merger with legacy Aphria, adopting the Tilray name. The majority of its sales are from the Canadian market and international medical cannabis exports, with U.S. sales including cannabidiol (CBD) products and alcoholic beverages.
